Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 6
Submit an article Journal homepage
2,889
Views
29
CrossRef citations to date
0
Altmetric
Original Research

Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

Ming ChengDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Brian H. SantichDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA;Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Hong XuDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Mahiuddin AhmedDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Morgan HuseImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
&
Nai-Kong V. CheungDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
Article: e1168557 | Received 18 Feb 2016, Accepted 14 Mar 2016, Published online: 15 Jun 2016

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Han Ping Loh, Farouq Bin Mahfut, Serene W Chen, Yuhan Huang, Jianxin Huo, Wei Zhang, Kong Peng Lam, Shengli Xu & Yuansheng Yang. (2023) Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies. mAbs 15:1.
Read now
Haitao Pan, Jiayu Liu, Wentong Deng, Jieyu Xing, Qing Li & Zhong Wang. (2018) Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy. International Journal of Nanomedicine 13, pages 3189-3201.
Read now
Di Wang, Yating Sun, Yange Liu, Fanchao Meng & Robert J. Lee. (2018) Clinical translation of immunoliposomes for cancer therapy: recent perspectives. Expert Opinion on Drug Delivery 15:9, pages 893-903.
Read now
Sameer Sait & Shakeel Modak. (2017) Anti-GD2 immunotherapy for neuroblastoma. Expert Review of Anticancer Therapy 17:10, pages 889-904.
Read now

Articles from other publishers (25)

Pierre Machy, Erwan Mortier & Stéphane Birklé. (2023) Biology of GD2 ganglioside: implications for cancer immunotherapy. Frontiers in Pharmacology 14.
Crossref
Madelyn Espinosa-Cotton & Nai-Kong V. Cheung. (2022) Bispecific antibodies for the treatment of neuroblastoma. Pharmacology & Therapeutics 237, pages 108241.
Crossref
Shun‐Yu Wu, Fu‐Gen Wu & Xiaoyuan Chen. (2022) Antibody‐Incorporated Nanomedicines for Cancer Therapy. Advanced Materials 34:24.
Crossref
Nora Berois, Alvaro Pittini & Eduardo Osinaga. (2022) Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives. Cancers 14:3, pages 645.
Crossref
Tsung-Yi Lin, Jeong A Park, Alan Long, Hong-Fen Guo & Nai-Kong V Cheung. (2021) Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 9:9, pages e003114.
Crossref
Felix Zirngibl, Sara M Ivasko, Laura Grunewald, Anika Klaus, Silke Schwiebert, Peter Ruf, Horst Lindhofer, Kathy Astrahantseff, Lena Andersch, Johannes H Schulte, Holger N Lode, Angelika Eggert, Kathleen Anders, Patrick Hundsdoerfer & Annette Künkele. (2021) GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Journal for ImmunoTherapy of Cancer 9:7, pages e002923.
Crossref
Paola Giussani, Alessandro Prinetti & Cristina Tringali. (2021) The Role of Sphingolipids in Cancer Immunotherapy. International Journal of Molecular Sciences 22:12, pages 6492.
Crossref
Magdalena Thurin. (2021) Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 40:3, pages 89-100.
Crossref
Emily Han-Chung Hsiue, Katharine M. Wright, Jacqueline Douglass, Michael S. HwangBrian J. Mog, Alexander H. Pearlman, Suman Paul, Sarah R. DiNapoli, Maximilian F. Konig, Qing Wang, Annika Schaefer, Michelle S. Miller, Andrew D. Skora, P. Aitana Azurmendi, Michael B. Murphy, Qiang Liu, Evangeline WatsonYana Li, Drew M. Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Sandra B. Gabelli & Shibin Zhou. (2021) Targeting a neoantigen derived from a common TP53 mutation . Science 371:6533.
Crossref
Brian H. Santich, Sarah M. Cheal, Mahiuddin Ahmed, Michael R. McDevitt, Ouathek Ouerfelli, Guangbin Yang, Darren R. Veach, Edward K. Fung, Mitesh Patel, Daniela Burnes Vargas, Aiza A. Malik, Hong-Fen Guo, Pat B. Zanzonico, Sebastien Monette, Adam O. Michel, Charles M. Rudin, Steven M. Larson & Nai K. Cheung. (2021) A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical Cancer Research 27:2, pages 532-541.
Crossref
Wilson Savino, Beatriz Chaves, Adriana Cesar Bonomo & Vinicius Cotta-de-Almeida. (2021) Integrin-directed antibody-based immunotherapy: focus on VLA-4. Immunotherapy Advances 1:1.
Crossref
Sayed Shahabuddin Hoseini, Madelyn Espinosa-Cotton, Hong-fen Guo & Nai-Kong V Cheung. (2020) Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies. Journal for ImmunoTherapy of Cancer 8:2, pages e001626.
Crossref
Anne M. Macpherson, Simon C. Barry, Carmela Ricciardelli & Martin K. Oehler. (2020) Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. Journal of Clinical Medicine 9:9, pages 2967.
Crossref
A. Barkhordari, K. Mahnam & H. Mirmohammad-Sadeghi. (2020) Designing a new bispecific tandem single-chain variable fragment antibody against tumor necrosis factor-α and interleukin-23 using in silico studies for the treatment of rheumatoid arthritis. Journal of Molecular Modeling 26:9.
Crossref
Jeong A. Park & Nai-Kong V. Cheung. (2020) Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of Clinical Oncology 38:16, pages 1836-1848.
Crossref
Jung Yoon Choi. (2020) Immunotherapy in Pediatric Solid Tumors. Clinical Pediatric Hematology-Oncology 27:1, pages 22-31.
Crossref
Brian H. Santich, Jeong A. Park, Hoa TranHong-Fen GuoMorgan Huse & Nai-Kong V. Cheung. (2020) Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Science Translational Medicine 12:534.
Crossref
Zahra Rashidijahanabad & Xuefei Huang. (2020) Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy. Seminars in Immunology 47, pages 101390.
Crossref
Roman V. Kholodenko, Daniel V. Kalinovsky, Igor I. Doronin, Eugene D. Ponomarev & Irina V. Kholodenko. (2019) Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations. Current Medicinal Chemistry 26:3, pages 396-426.
Crossref
Anupa Kudva & Shakeel Modak. 2019. Neuroblastoma. Neuroblastoma 147 173 .
Irina V. Kholodenko, Daniel V. Kalinovsky, Igor I. Doronin, Sergey M. Deyev & Roman V. Kholodenko. (2018) Neuroblastoma Origin and Therapeutic Targets for Immunotherapy. Journal of Immunology Research 2018, pages 1-25.
Crossref
Erika N. Cline, Maíra Assunção Bicca, Kirsten L. Viola & William L. Klein. (2018) The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. Journal of Alzheimer's Disease 64:s1, pages S567-S610.
Crossref
Adriano Sebollela, Erika N. Cline, Izolda Popova, Kevin Luo, Xiaoxia Sun, Jay Ahn, Milena A. Barcelos, Vanessa N. Bezerra, Natalia M. Lyra e Silva, Jason Patel, Nathalia R. Pinheiro, Lei A. Qin, Josette M. Kamel, Anthea Weng, Nadia DiNunno, Adrian M. Bebenek, Pauline T. Velasco, Kirsten L. Viola, Pascale N. Lacor, Sergio T. Ferreira & William L. Klein. (2017) A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid-β oligomers. Journal of Neurochemistry 142:6, pages 934-947.
Crossref
Shuanglin Han, Olivier Latchoumanin, Guang Wu, Gang Zhou, Lionel Hebbard, Jacob George & Liang Qiao. (2017) Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors. Cancer Letters 390, pages 188-200.
Crossref
Madelyn Espinosa-Cotton & Nai-Kong V. Cheung. (2022) Bispecific Antibodies for the Treatment of Neuroblastoma. SSRN Electronic Journal.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.